Company news
ImmunityBio, Inc. news in 2020
ImmunityBio, Inc.'s news releases, calls and decks from 2020, newest first.
ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate
December 20, 2020
ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company
December 20, 2020
ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates
December 9, 2020
ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
November 22, 2020
NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare Conference
November 17, 2020
ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study
November 9, 2020
ImmunityBio’s hAd5 COVID-19 Vaccine Candidate Stimulates Memory T-Cell Recall in Patients Infected with SARS-CoV-2
November 8, 2020
NantKwest Names Richard Adcock Chief Executive Officer
October 25, 2020
ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation COVID-19 Vaccine Candidate Delivering Both Spike and Nucleocapsid of SARS-CoV-2
October 20, 2020
FDA Authorizes Phase 1 Trial of ImmunityBio’s Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both T Cell and Antibody Immunity
October 14, 2020
NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All Approved Standards of Care
October 5, 2020
NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit
September 20, 2020
NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics
August 23, 2020
Cord Blood Registry (CBR®) By Generate Life Sciences Partners With NantKwest To Develop COVID-19 Treatment
August 9, 2020
ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins
August 2, 2020
NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 28, 2020
NantKwest Announces Pricing of Public Offering of Common Stock
June 24, 2020
NantKwest Announces Proposed Public Offering of Common Stock
June 23, 2020
NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested
June 9, 2020
ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine
May 26, 2020
NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference
May 25, 2020
NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients
May 17, 2020
NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer
May 13, 2020
NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference
April 28, 2020
NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter
April 13, 2020
NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells
March 18, 2020
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein
January 13, 2020
Decks in 2020
- NantKwest — Merger or Acquisition (December 2020)
Merger or acquisition · 31 slides · Dec 21, 2020
- LifeSci Advisors Investor Call, May 27, 2020
Conference · 18 slides · May 27, 2020